Insider Selling: Septerna (NASDAQ:SEPN) COO Sells $1,100,000.00 in Stock

Septerna, Inc. (NASDAQ:SEPN) COO Elizabeth Bhatt sold 25,000 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $44.00, for a total value of $1,100,000.00. Following the completion of the transaction, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at approximately $7,665,196. The trade was a 12.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Septerna Price Performance

Septerna stock opened at $44.50 on Friday. The business has a 50 day simple moving average of $35.83 and a 200 day simple moving average of $29.64. The company has a market capitalization of $2.08 billion, a PE ratio of -82.41 and a beta of 2.29. Septerna, Inc. has a one year low of $10.74 and a one year high of $51.10.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.14. The firm had revenue of $26.75 million for the quarter, compared to analysts’ expectations of $19.22 million. Septerna had a negative return on equity of 9.57% and a negative net margin of 24.51%. Equities analysts anticipate that Septerna, Inc. will post -1.36 earnings per share for the current fiscal year.

Institutional Trading of Septerna

Large investors have recently made changes to their positions in the business. Group One Trading LLC lifted its position in Septerna by 111.8% during the 4th quarter. Group One Trading LLC now owns 944 shares of the company’s stock worth $26,000 after buying an additional 8,955 shares in the last quarter. Global Retirement Partners LLC bought a new stake in Septerna during the 4th quarter worth about $35,000. Russell Investments Group Ltd. acquired a new stake in Septerna in the 3rd quarter valued at about $36,000. Caitong International Asset Management Co. Ltd acquired a new stake in Septerna in the 4th quarter valued at about $53,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Septerna in the fourth quarter worth about $61,000.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on SEPN shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a research report on Friday, July 17th. JonesTrading boosted their price target on shares of Septerna from $43.00 to $62.00 and gave the company a “buy” rating in a research report on Thursday. Guggenheim upped their price objective on shares of Septerna from $45.00 to $51.00 and gave the stock a “buy” rating in a research note on Tuesday. Stifel Nicolaus set a $49.00 price objective on shares of Septerna in a report on Tuesday. Finally, HC Wainwright lifted their target price on shares of Septerna from $40.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Septerna presently has an average rating of “Moderate Buy” and an average price target of $51.33.

Key Septerna News

Here are the key news stories impacting Septerna this week:

• Positive Sentiment: HC Wainwright significantly improved its Septerna earnings outlook, reducing its projected FY2026 loss to $1.15 per share from $2.17 and its FY2027 loss to $1.41 from $3.21. The firm retained a “Buy” rating and a $60 price target, suggesting analysts expect improved financial performance. HC Wainwright forecasts strong price appreciation for Septerna
• Positive Sentiment: HC Wainwright also raised its quarterly 2026 and 2027 EPS forecasts, with projected losses narrowing across every period. The revisions indicate better-than-expected operating trends or a more favorable development outlook for the clinical-stage biotechnology company. HC Wainwright earnings estimate revisions
• Positive Sentiment: JonesTrading raised its price target from $43 to $62 and assigned a “Buy” rating, while Wells Fargo increased its target from $48 to $50 and maintained an “Overweight” rating. These actions reinforce a favorable Wall Street view following Septerna’s recent earnings beat. JonesTrading raises Septerna price target
• Positive Sentiment: Septerna’s latest quarterly results exceeded expectations: the company reported a $0.29-per-share loss versus the anticipated $0.43 loss, while revenue of $26.75 million topped the $19.22 million consensus estimate. Septerna shares rise on better-than-expected earnings
• Negative Sentiment: COO Elizabeth Bhatt sold 25,000 shares for approximately $1.1 million at an average price of $44, reducing her ownership by 12.55%. She still holds 174,209 shares, but the insider sale could weigh on sentiment—particularly after the stock’s strong recent advance. Septerna COO insider share sale

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.